甲胎蛋白对NIH3T3细胞和人肝癌Bel7402细胞增殖的促进作用

目的:观察甲胎蛋白对细胞增殖的影响。方法:用从人脐带血清中提取的甲胎蛋白,作用于体外培养的NIH3T3细胞和人肝癌Bel7402细胞,运用MTT染色计数法,细胞周期时相测定和3H脱氧胸腺嘧啶核苷(3H-TdR)参入法等指标检测细胞增殖状况。结果:甲胎蛋白(10～80mg·L-1)作用24h后,对NIH3T3细胞、人肝癌Bel7402细胞均有不同程度的促增殖作用,甲胎蛋白的单克隆抗体能阻断这种作用。结论:甲胎蛋白是促进某些新生细胞或肿瘤细胞增殖的内源性物质。     

血清GP73联合AFP在肝细胞癌诊断中的价值

目的 探讨血清高尔基体蛋白73（GP73）与甲胎蛋白（AFP）联合检测在肝细胞癌（HCC）诊断中的价值。方法 收集2011年2月至2012年1月30例HCC患者（HCC组）、30例肝硬化患者（肝硬化组）和20例健康人（健康对照组）的血清,分别用酶联免疫吸附法（ELISA）和电化学发光免疫法（ECLIA）检测各组血清中GP73和AFP水平。结果 HCC组、肝硬化组和健康对照组血清GP73水平分别为（251.9±130.2）ng／ml、（74.7±40.6）ng／ml和（12.2±4.0）ng／ml,AFP水平分别为（141.6±158.3）ng／ml、（36.0±35.0）ng／ml和（2.2±1.5）ng／ml。GP73 检测HCC的敏感度为76.7％,特异度82.0％,约登指数58.7％,准确度80.0％。AFP检测HCC的敏感度为63.3％,特异度80.0％,约登指数43.3％,准确度68.8％。两者联合检测的敏感度为86.7％,特异度78.0％,约登指数64.7％,准确度81.3％。结论 HCC患者血清中GP73和AFP水平较高,两者联合检测可以显著提高HCC的诊断能力。     

血清巨噬细胞抑制因子1联合甲胎蛋白异质体3含量检测在原发性肝癌诊断中的价值

目的 探讨酶联免疫吸附（ELISA）法检测血清巨噬细胞抑制因子Ⅰ（MIC-1）联合甲胎蛋白异质体3（AFP-L3）对原发性肝癌的诊断价值.方法 选择116例临床确诊的原发性肝癌患者,应用ELISA法检测患者血清MIC-1和AFP-L3含量,分析二者联合检测在原发性肝癌诊断中的价值.结果 原发性肝癌组AFP-L3浓度为（127.12±51.43）ng/ml,明显高于正常对照组的（27.11±7.26） ng/ml（P＜ 0.001）,以AFP-L3＞ 38.0 ng/ml为临界值时,灵敏度为85.34％（99/116）,特异度为88.33％（53/60）,诊断准确度为86.36％（152/176）;原发性肝癌组MIC-1浓度为（3140.43±1138.23）pg/ml,明显高于正常对照组的（701.88±302.34） pg/ml（P＜0.001）,灵敏度为91.38％（106/116）,特异度为85.00％（51/60）,诊断准确度为89.20％（157/176）.二者联合检测灵敏度为83.62％（97/116）,特异度为91.67％（55/60）,诊断准确度为86.36％（152/176）.结论 MIC-1联合AFP-L3检测可提高原发性肝癌诊断的特异度,具有一定的临床价值.     

榄香注射液及华蟾素注射液分别联合TACE治疗中晚期原发性肝癌临床研究

目的:观察比较榄香注射液及华蟾素注射液分别联合肝动脉导管化疗栓塞治疗中晚期原发性肝癌的临床疗效及不良反应发生率的差异。方法:纳入104例2018年8月—2020年1月于肿瘤科治疗的中晚期原发性肝癌患者作为研究对象,按照治疗方案的不同随机分成2组各52例。2组患者均给予肝动脉导管化疗栓塞(TACE)治疗1次,华蟾素注射液组予华蟾素注射液10 m L加入到5%葡萄糖注射液500 m L中静脉滴注,每天1次。榄香注射液组加用榄香注射液静脉滴注,每次0.4 g,每天1次,2组连续治疗15 d后休息15 d,连续治疗2个疗程。观察比较2组临床疗效、肝功能指标[(谷丙转氨酶(ALT)、谷草转氨酶(AST)及总胆红素(TBil)]的变化及甲胎蛋白(AFP)、卡氏评分(KPS)和肿瘤体积的变化,以及不良反应发生率的差异。结果:临床疗效总有效率榄香注射液组88.46%,华蟾素注射液组71.15%,2组比较,差异有统计学意义(P<0.05)。治疗后,2组血清ALT、AST和TBil水平较治疗前均显著降低,差异均有统计学意义(P<0.05);2组间血清ALT、AST和TBil水平相比较,差异无统...     

Enhanced Liver Metastatic Potential of Alpha-fetoprotein-producing Human Gastric Carcinoma after Carbon Tetrachloride-induced Liver Damage in Nude Mice

The liver metastatic potential of alpha-fetoprotein (AFP)-producing human gastric carcinoma (NSC-3) was examined in male, BALB/c, nude mice. Metastatic nodules in the liver were produced by intrasplenic (IS) injection of tumor cell suspension prepared by trypsinization from subcutaneous NSC-3 tumor. The serum AFP level increased exponentially after IS injection along with the growth of metastatic nodules in the liver, and a positive correlation was observed between the estimated weight of metastatic nodules and serum AFP level. To investigate the effect of liver damage by carbon tetrachloride (CCI₄) on the metastatic potential of NSC-3 cells injected intrasplenlcally, the mice were divided into 4 groups: Group 1 received IS injection of 1×10⁶ of NSC-3 cells without CCI₄, treatment; Groups 2, 3 and 4 received IS injection 7 days, 2 days and 1 day after CCI₄ treatment, respectively. All mice were killed 64 days after IS injection. The incidence of liver metastasis was 80% in Group 1, but 100% in Groups 2, 3 and 4. The mean numbers of metastatic nodules per liver were 4.2 in Group 1, 16.8 in Group 2, 18.0 in Group 3 and 44.5 in Group 4. Significant differences in the mean numbers of metastatic nodules were observed between Group 4 and the other groups. It was clearly demonstrated that the metastatic potential of AFP-producing human gastric carcinoma cells (NSC-3) is enhanced in the situation prevailing after liver parenchymal cells are damaged by CCI₄.     

Ask the expert

The editors invite questions for this section     

Immature ovarian teratoma with peritoneal gliomatosis and elevated serum alpha-fetoprotein associated with a second mature teratoma

A 7-year-old girl had a huge immature grade 2 teratoma of the left ovary with peritoneal gliomatosis and elevated serum alpha-fetoprotein (AFP). The serum AFP level reached 3543 ng/ml and returned to normal after left salpingo-oophorectomy and chemotherapy. Twenty-two months later, a second mature teratoma was removed from the left subdiaphragmatic region. The AFP level had been within the normal range and the patient had been symptom-free for 3 years following the previous operation. AFP was positive in the tubular epithelium of the immature tissues on immunohistochemical study. Offprint requests to: A. Hokama     

Protein induced by vitamin K absence or antagonist-Ⅱ versus alpha-fetoprotein in the diagnosis of hepatocellular carcinoma: A systematic review with meta-analysis

Background: As a promising biomarker of hepatocellular carcinoma(HCC), protein induced by vitamin K absence or antagonist-Ⅱ(PIVKA-Ⅱ) has been studied extensively. However, its diagnostic capability varies across HCC studies. This study aimed to compare the performance of PIVKA-Ⅱ with alpha-fetoprotein(AFP) in the diagnosis of HCC. Data sources: A systematic literature search was conducted to identify the studies from MEDLINE, Embase and Cochrane Library Databases, which were published up to December 20, 2017 to compare the diagnostic capability of PIVKA-Ⅱ and AFP for HCC. The data were pooled using random effects model. Pooled sensitivity and specificity were calculated. Summary receiver operating characteristic curve(ROC) was employed to evaluate the diagnostic accuracy of each marker. Results: Thirty-one studies were included. The pooled sensitivity(95% CI) of PIVKA-Ⅱ and AFP was 0.66(0.65–0.68) and 0.66(0.65–0.67), respectively in diagnosis of HCC; and the corresponding pooled specificity(95% CI) was 0.89(0.88–0.90) and 0.84(0.83–0.85), respectively. The area under the ROC curve(AUC) of PIVKA-Ⅱ and AFP was 0.856(0.817–0.895) and 0.770(0.728–0.811), respectively. Subgroup analysis showed that PIVKA-Ⅱ was superior to AFP in terms of the AUC for both small HCC( 3 cm) [0.863(0.825–0.901) vs 0.717(0.658–0.776)] and large HCC( ≥ 3 cm) [0.854(0.811–0.897) vs 0.729(0.682–0.776)]; for American [0.926(0.897–0.955) vs 0.698(0.594–0.662)], European [0.772(0.743–0.801) vs 0.628(0.594–0.662)], Asian [0.838(0.812–0.864) vs 0.785(0.764–0.806)] and African [0.812(0.794–0.840) vs 0.721(0.675–0.767)] HCC patients; and for HBV-related [0.909(0.866–0.951) vs 0.714(0.673–0.755)] and mixed-etiology [0.847(0.821–0.873) vs 0.794(0.772–0.816)] HCC. Conclusion: This meta-analysis indicates that PIVKA-Ⅱ is better than AFP in terms of the accuracy for diagnosing HCC, regardless of tumor size, patient ethnic group, or HCC etiology.     

Blood Serum Alpha Fetoprotein Enhancer Binding Protein,a Tumor Suppressor,Decreases in Chronic HBV Hepatitis Patients as Hepatocellular Cancer Appears

Chronic hepatitis increases the risk of hepatocellular carcinoma (HCC). To test whether circulating proteins reflect hepatic carcinogenesis, sera from patients and controls were albumin depleted, enriched for glycoproteins, digested with trypsin, and subjected to reverse phase chromatography and tandem mass spectrometry. Alpha-fetoprotein enhancer binding protein (AFPebp), a tumor suppressor, was repeatedly identified in sera from chronic HBV hepatitis patients. We independently identified and quantified AFPebp with a deuterated, phenylisocyanate-labeled synthetic peptide standard. Elevated AFPebp levels in sera from chronic HBV hepatitis patients decreased as cancer developed. These data suggest that rising AFPebp levels in chronic HBV hepatitis may be protective, while falling levels may contribute to HCC development.     

依据卫生行业标准建立产前监测和开放性神经管缺损诊断AFP中位值及评价

目的 依据卫生行业标准(WS/T247-2005)推荐方法建立产前监测和开放性神经管缺损诊断AFP中位值.方法 分别用100例15-20孕周的孕中期母体血清检测AFP结果计算AFP中位值,与累积中位值相比较,并评价中位值与孕周的线性关系.结果 按标准方法计算的中位值与累积中位值无明显差异,与孕周呈良好的半对数线性关系,其筛查总阳性率为1.09%.结论 卫生行业标准(WS/T247-2005)推荐的产前监测和开放性神经管缺损诊断AFP中位值建立方法与大批量监测数据计算结果高度一致,在尽量降低数据量的前提下,保证了中位值计算结果的可靠性.